
Daiichi-Sankyo will pay the US government and state Medicaid programmes $39 million to resolve claims that it violated the False …

The US Food and Drug Administration has shown Daiichi-Sankyo’s anti-clotting drug Savaysa the green light to reduce the risk of …
Daiichi-Sankyo has been cleared of any wrongdoing in relation to the ABPI Code after one of its representatives was accused …
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion

